FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4251646064> ?p ?o ?g. }

• W4251646064 endingPage "379" @default.
• W4251646064 startingPage "364" @default.
• W4251646064 abstract "Study QuestionWhat is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference?Summary AnswerInternational evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS.What Is Known AlreadyPrevious guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist.Study Design, Size, DurationInternational evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength.Participants/Materials, Setting, MethodsGovernance included a six continent international advisory and a project board, five guideline development groups, and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels.Main Results and the Role of ChanceThe evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: i) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; ii) reducing unnecessary testing; iii) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and iv) emphasizing evidence based medical therapy and cheaper and safer fertility management.Limitations, Reasons for CautionOverall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided.Wider Implications of the FindingsThe international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program.Study Funding/Competing Interest(S)The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine. Guideline development group members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Full details of conflicts declared across the guideline development groups are available at https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline in the Register of disclosures of interest. Of named authors, Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Laven declared grants from Ferring, Euroscreen and personal fees from Ferring, Euroscreen, Danone and Titus Healthcare. Prof. Norman has declared a minor shareholder interest in an IVF unit. The remaining authors have no conflicts of interest to declare. The guideline was peer reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREEII criteria and underwent methodological review. This guideline was approved by all members of the guideline development groups and was submitted for final approval by the NHMRC. What is the recommended assessment and management of women with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? International evidence-based guidelines including 166 recommendations and practice points, addressed prioritized questions to promote consistent, evidence-based care and improve the experience and health outcomes of women with PCOS. Previous guidelines either lacked rigorous evidence-based processes, did not engage consumer and international multidisciplinary perspectives, or were outdated. Diagnosis of PCOS remains controversial and assessment and management are inconsistent. The needs of women with PCOS are not being adequately met and evidence practice gaps persist. International evidence-based guideline development engaged professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Appraisal of Guidelines for Research and Evaluation (AGREE) II-compliant processes were followed, with extensive evidence synthesis. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation and ultimately recommendation strength. Governance included a six continent international advisory and a project board, five guideline development groups, and consumer and translation committees. Extensive health professional and consumer engagement informed guideline scope and priorities. Engaged international society-nominated panels included pediatrics, endocrinology, gynecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, public health and other experts, alongside consumers, project management, evidence synthesis, and translation experts. Thirty-seven societies and organizations covering 71 countries engaged in the process. Twenty face-to-face meetings over 15 months addressed 60 prioritized clinical questions involving 40 systematic and 20 narrative reviews. Evidence-based recommendations were developed and approved via consensus voting within the five guideline panels, modified based on international feedback and peer review, with final recommendations approved across all panels. The evidence in the assessment and management of PCOS is generally of low to moderate quality. The guideline provides 31 evidence based recommendations, 59 clinical consensus recommendations and 76 clinical practice points all related to assessment and management of PCOS. Key changes in this guideline include: i) considerable refinement of individual diagnostic criteria with a focus on improving accuracy of diagnosis; ii) reducing unnecessary testing; iii) increasing focus on education, lifestyle modification, emotional wellbeing and quality of life; and iv) emphasizing evidence based medical therapy and cheaper and safer fertility management. Overall evidence is generally low to moderate quality, requiring significantly greater research in this neglected, yet common condition, especially around refining specific diagnostic features in PCOS. Regional health system variation is acknowledged and a process for guideline and translation resource adaptation is provided. The international guideline for the assessment and management of PCOS provides clinicians with clear advice on best practice based on the best available evidence, expert multidisciplinary input and consumer preferences. Research recommendations have been generated and a comprehensive multifaceted dissemination and translation program supports the guideline with an integrated evaluation program. The guideline was primarily funded by the Australian National Health and Medical Research Council of Australia (NHMRC) supported by a partnership with ESHRE and the American Society for Reproductive Medicine. Guideline development group members did not receive payment. Travel expenses were covered by the sponsoring organizations. Disclosures of conflicts of interest were declared at the outset and updated throughout the guideline process, aligned with NHMRC guideline processes. Full details of conflicts declared across the guideline development groups are available at https://www.monash.edu/medicine/sphpm/mchri/pcos/guideline in the Register of disclosures of interest. Of named authors, Dr Costello has declared shares in Virtus Health and past sponsorship from Merck Serono for conference presentations. Prof. Laven declared grants from Ferring, Euroscreen and personal fees from Ferring, Euroscreen, Danone and Titus Healthcare. Prof. Norman has declared a minor shareholder interest in an IVF unit. The remaining authors have no conflicts of interest to declare. The guideline was peer reviewed by special interest groups across our partner and collaborating societies and consumer organizations, was independently assessed against AGREEII criteria and underwent methodological review. This guideline was approved by all members of the guideline development groups and was submitted for final approval by the NHMRC." @default.
• W4251646064 created "2022-05-12" @default.
• W4251646064 creator A5000416978 @default.
• W4251646064 creator A5002404708 @default.
• W4251646064 creator A5003517853 @default.
• W4251646064 creator A5004045329 @default.
• W4251646064 creator A5004409149 @default.
• W4251646064 creator A5005148022 @default.
• W4251646064 creator A5006353998 @default.
• W4251646064 creator A5007211868 @default.
• W4251646064 creator A5009207059 @default.
• W4251646064 creator A5009732804 @default.
• W4251646064 creator A5012931929 @default.
• W4251646064 creator A5013084020 @default.
• W4251646064 creator A5016388668 @default.
• W4251646064 creator A5018688881 @default.
• W4251646064 creator A5018904549 @default.
• W4251646064 creator A5020019905 @default.
• W4251646064 creator A5021535686 @default.
• W4251646064 creator A5021726925 @default.
• W4251646064 creator A5022380857 @default.
• W4251646064 creator A5028123546 @default.
• W4251646064 creator A5029656513 @default.
• W4251646064 creator A5029902314 @default.
• W4251646064 creator A5030339683 @default.
• W4251646064 creator A5031127867 @default.
• W4251646064 creator A5033369161 @default.
• W4251646064 creator A5034278478 @default.
• W4251646064 creator A5034344913 @default.
• W4251646064 creator A5038117104 @default.
• W4251646064 creator A5039259985 @default.
• W4251646064 creator A5039468733 @default.
• W4251646064 creator A5040461677 @default.
• W4251646064 creator A5041298016 @default.
• W4251646064 creator A5042275051 @default.
• W4251646064 creator A5044684679 @default.
• W4251646064 creator A5046096833 @default.
• W4251646064 creator A5047480968 @default.
• W4251646064 creator A5047638040 @default.
• W4251646064 creator A5049687573 @default.
• W4251646064 creator A5050168952 @default.
• W4251646064 creator A5052123323 @default.
• W4251646064 creator A5054914485 @default.
• W4251646064 creator A5055934536 @default.
• W4251646064 creator A5056701614 @default.
• W4251646064 creator A5057365378 @default.
• W4251646064 creator A5060447216 @default.
• W4251646064 creator A5060831453 @default.
• W4251646064 creator A5061097254 @default.
• W4251646064 creator A5061896976 @default.
• W4251646064 creator A5065813469 @default.
• W4251646064 creator A5066032677 @default.
• W4251646064 creator A5067531230 @default.
• W4251646064 creator A5069030846 @default.
• W4251646064 creator A5069955487 @default.
• W4251646064 creator A5071085683 @default.
• W4251646064 creator A5071954469 @default.
• W4251646064 creator A5072698381 @default.
• W4251646064 creator A5073911312 @default.
• W4251646064 creator A5075073062 @default.
• W4251646064 creator A5075236929 @default.
• W4251646064 creator A5077162723 @default.
• W4251646064 creator A5079834835 @default.
• W4251646064 creator A5081052860 @default.
• W4251646064 creator A5084557084 @default.
• W4251646064 creator A5085070599 @default.
• W4251646064 creator A5085461979 @default.
• W4251646064 creator A5086143274 @default.
• W4251646064 creator A5089634900 @default.
• W4251646064 creator A5090356838 @default.
• W4251646064 creator A5090795384 @default.
• W4251646064 creator A5091356737 @default.
• W4251646064 date "2018-08-01" @default.
• W4251646064 modified "2023-10-18" @default.
• W4251646064 title "Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome" @default.
• W4251646064 cites W1577097214 @default.
• W4251646064 cites W1963543729 @default.
• W4251646064 cites W2053105417 @default.
• W4251646064 cites W2054117560 @default.
• W4251646064 cites W2058294720 @default.
• W4251646064 cites W2120973019 @default.
• W4251646064 cites W2129688566 @default.
• W4251646064 cites W2155715955 @default.
• W4251646064 cites W2163955607 @default.
• W4251646064 cites W2481420451 @default.
• W4251646064 cites W2558741448 @default.
• W4251646064 cites W2610407602 @default.
• W4251646064 doi "https://doi.org/10.1016/j.fertnstert.2018.05.004" @default.
• W4251646064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30033227" @default.
• W4251646064 hasPublicationYear "2018" @default.
• W4251646064 type Work @default.
• W4251646064 citedByCount "644" @default.
• W4251646064 countsByYear W42516460642018 @default.
• W4251646064 countsByYear W42516460642019 @default.
• W4251646064 countsByYear W42516460642020 @default.
• W4251646064 countsByYear W42516460642021 @default.
• W4251646064 countsByYear W42516460642022 @default.
• W4251646064 countsByYear W42516460642023 @default.

• next